MSD posts a victory and defeat for anti-TL1A in skin condition and rare lung disease

MSD is currently evaluating anti-TL1A drug, tulisokibart in six different indications following the therapy's discontinuation in SSc-ILD. The post MSD posts a victory and defeat for anti-TL1A in skin condition and rare lung disease appeared first on Clinical Trials Arena .